Immune Response among Different Types of SARS-CoV-2 Vaccines in Iraq
Abstract
Introduction: COVID-19 vaccine have been indicated to successfully decrease the hazard for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection furthermore associated hospitalisations.
Objective: To study the immune response among different types of SARS-CoV-2 vaccines.
Methods: This study includes 100 vaccinated individuals (43 Sinopharm, 30 AstraZeneca and 27 Pfizer) with one or two doses from different health centres in Baghdad. During the period from April 2021 to the end of May 2021, SARS-CoV-2 IgG and SARS-CoV-2 IgM levels were detected using AFIAS-6 device depending on FIA (Fluorescence Immunoassay) technique.
Results: 93% of the cases were positive for IgG levels, and negative in 7% cases. Coronavirus IgM concentrations for all individuals were negative. The highest IgG mean level was seen in vaccinated persons with Pfizer than AstraZeneca (34.41, 26.29 respectively) and the lowest mean value was detected in Sinopharm (23.76). There was a significant elevation in IgG levels in the previously infected group in comparison with non-infected individuals. IgG levels decrease in antibody responses to SARS-CoV-2 in older individuals compared to younger participants. Also, results reported that SARS-CoV-2 IgG levels increased in males who were vaccinated with Pfizer and AstraZeneca more than females, while there is a significant decrease in IgG levels in vaccinated males with Sinopharm as compared to females.
Conclusion: Different vaccines against SARS-CoV-2 produce different levels of IgG.
How to cite this article:
Al-Asadi AB, Al-Nuaimi BN, Abdul-Ghani MN, Al-Maadhidi JF. Immune Response among Different Types of SARS-CoV-2 Vaccines in Iraq. Special Issue - COVID-19 & Other Communicable Disease. 2022;103-108.
DOI: https://doi.org/10.24321/0019.5138.202216
References
Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020 Aug;56(2):106054. [PubMed] [Google Scholar]
World Health Organization [Internet]. Coronavirus Disease (COVID-19) weekly epidemiological update and weekly operational update; [cited 2021 May 21]. Available from: https://covid19.who.int/ [Google Scholar]
Narasimhan M, Mahimainathan L, Araj E, Clark AE, Wilkinson K, Yekkaluri S, Tiro J, Lee FM, Balani J, Sarode R, Singal AG, Muthukumar A. Expanding COVID-19 vaccine availability: role for Combined Orthogonal Serology Testing (COST). Vaccines (Basel). 2021 Apr;9(4):376. [PubMed] [Google Scholar]
World Health Organization [Internet]. The Sinopharm COVID-19 vaccine: what you need to know; [cited 2021 Sep 2]. Available from: https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know
Mullard A. COVID-19 vaccine development pipeline gears up. The Lancet. 2020 Jun;395(10239):1751-2. [PubMed] [Google Scholar]
World Health Organization [Internet]. The Oxford/AstraZeneca COVID-19 vaccine: what you need to know; [cited 2021 Sep 2]. Available from: https://www.who.int/news-room/feature-stories/detail/the-oxford-astrazeneca-covid-19-vaccine-what-you-need-to-know
World Health Organization [Internet]. Pfizer BioNTech COVID-19 vaccine: what you need to know; [cited 2022 Jan 21]. Available from: https://www.who.int/news-room/feature-stories/detail/who-can-take-the-pfizer-biontech-covid-19--vaccine
Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, Nakao C, Rayaprolu V, Rawlings SA, Peters B, Krammer F, Simon V, Saphire EO, Smith DM, Weiskopf D, Sette A, Crotty S. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb;371(6529):eabf4063. [PubMed] [Google Scholar]
Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY, Cipolla M, Viant C, Barnes CO, Bram Y, Breton G, Hägglöf T, Mendoza P, Hurley A, Turroja M, Gordon K, Millard KG, Ramos V, Schmidt F, Weisblum Y, Jha D, Tankelevich M, Martinez-Delgado G, Yee J, Patel R, Dizon J, Unson-O’Brien C, Shimeliovich I, Robbiani DF, Zhao Z, Gazumyan A, Schwartz RE, Hatziioannou T, Bjorkman PJ, Mehandru S, Bieniasz PD, Caskey M, Nussenzweig MC. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021 Mar;591(7851):639-44. [PubMed] [Google Scholar]
SAS. Statistical Analysis System, User’s Guide. Statistical. Version 9. 1st ed. SAS. Inst Inc Cary NC USA; 2012.
World Health Organization [Internet]. Draft landscape of COVID-19 candidate vaccines; [cited 2020 Dec 10].
Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
Doroftei B, Ciobica A, Ilie OD, Maftei R, Ilea C. Mini-review discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics (Basel). 2021 Apr;11(4):579. [PubMed] [Google Scholar]
Hotez PJ, Nuzhath T, Callaghan T, Colwell B. COVID-19 vaccine decisions: considering the choices and opportunities. Microbes Infect. 2021 May-Jun;23(4-5):104811. [PubMed] [Google Scholar]
Bauer G. The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2. Int J Infect Dis. 2021 May;106:61-4. [PubMed] [Google Scholar]
Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, Frias EC, Stewart JL, Van Eyk JE, Braun JG, Cheng S, Sobhani K. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021 Jun;27(6):981-4. [PubMed] [Google Scholar]
Gobbi F, Buonfrate D, Moro L, Rodari P, Piubelli C, Caldrer S, Riccetti S, Sinigaglia A, Barzon L. Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection. Viruses. 2021 Mar;13(3):422. [PubMed] [Google Scholar]
Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, Bermúdez-González MC, Bielak DA, Carreño JM, Chernet RL, Eaker LQ, Ferreri ED, Floda DL, Gleason CR, Hamburger JZ, Jiang K, Kleiner G, Jurczyszak D, Matthews JC, Mendez WA, Nabeel I, Mulder LCF, Raskin AJ, Russo KT, Salimbangon AT, Saksena M, Shin AS, Singh G, Sominsky LA, Stadlbauer D, Wajnberg A, Simon V. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021 Apr;384(14):1372-4. [PubMed] [Google Scholar]
Sasikala M, Shashidhar J, Deepika G, Ravikanth V, Krishna VV, Sadhana Y, Pragathi K, Reddy DN. Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individuals. Int J Infect Dis. 2021 Jul;108:183-6. [PubMed] [Google Scholar]
Blain H, Tuaillon E, Gamon L, Pisoni A, Miot S, Picot MC, Bousquet J. Spike antibody levels of nursing home residents with or without prior COVID-19 3 weeks after a single BNT162b2 vaccine dose. JAMA. 2021 May;325(18):1898-9. [PubMed] [Google Scholar]
Lombardi A, Bozzi G, Ungaro R, Villa S, Castelli V, Mangioni D, Muscatello A, Gori A, Bandera A. MINI REVIEW Immunological consequences of immunization with COVID-19 mRNA vaccines: preliminary results. Front Immunol. 2021 Mar;12:657711. [PubMed] [Google Scholar]
Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, Nakao C, Rayaprolu V, Rawlings SA, Peters B, Krammer F, Simon V, Saphire EO, Smith DM, Weiskopf D, Sette A, Crotty S. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb;371(6529):eabf4063. [PubMed] [Google Scholar]
Müller L, Andrée M, Moskorz W, Drexler I, Walotka L, Grothmann R, Ptok J, Hillebrandt J, Ritchie A, Rabl D, Ostermann PN, Robitzsch R, Hauka S, Walker A, Menne C, Grutza R, Timm J, Adams O, Schaal H. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis. 2021 Dec;73(11):2065-72. [PubMed] [Google Scholar]
Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing. 2021 Mar;50(2):279-83. [PubMed] [Google Scholar]
Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, Li T, Margolick JB, Pawelec G, Leng SX. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev. 2021 Jan;65:101205. [PubMed] [Google Scholar]
Schenkelberg T. Vaccine-induced protection in aging adults and pandemic response. Biochem Biophys Res Commun. 2021 Jan;538:218-20. [PubMed] [Google Scholar]
Klein SL, Pekosz A. Sex-based biology and the rational design of influenza vaccination strategies. J Infect Dis. 2014 Jul;209(suppl 3):S114-9. [PubMed] [Google Scholar]
World Health Organization [Internet]. Critical sex and gender considerations for equitable research, development and delivery of COVID-19 vaccines; [cited 2021 Apr 18]. Available from: https://www.who.int/publications/m/item/critical-sex-and-gender-considerations-for-equitable-research-development-and-delivery-of-covid-19-vaccines
Copyright (c) 2022 Author's
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
